Risk factors for cardiovascular disease and hormone therapy in women

Heart

Volumn 92, Issue SUPPL. 3, 2006, Pages

  Collins, P ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID; SEX HORMONE;

BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; DIABETES MELLITUS; HEART DISEASE; HORMONAL THERAPY; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

AGE FACTORS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DIABETIC ANGIOPATHIES; EXERCISE; FEMALE; GONADAL STEROID HORMONES; HORMONE REPLACEMENT THERAPY; HUMANS; LIFE STYLE; LIPIDS; RISK FACTORS; SMOKING;

EID: 33646256322     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2005.071787     Document Type: Review

References (47)

1. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. J Cardiopulm Rehabil 2005;25:56-7.
2. Lloyd-Jones DM, Larson MG, Beiser A, et al. Lifetime risk of developing coronary heart disease. Lancet 1999;353:89-92.
3. Lloyd-Jones DM, Wilson PW, Larson MG, et al. Lifetime risk of coronary heart disease by cholesterol levels at selected ages. Arch Intern Med 2003;163:1966-72.
4. Wenger NK. Coronary heart disease: an older woman's major health risk. BMJ 1997;315:1085-90.
5. Castelli WP, Garrison RJ, Dawber TR, et al. The filter cigarette and coronary heart disease: the Framingham study. Lancet 1981;2:109-13.
6. Bolego C, Poli A, Paolelti R. Smoking and gender. Carodiovasc Res 2002;53:568-76.
7. LaRosa JC, Hunninghake D, Bush D, et al. The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The task force on cholesterol issues, American Heart Association. Circulation 1990;81:1721-33.
8. Abbott RD, Wilson PW, Kannel WB, et al. High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction. The Framingham study. Arteriosclerosis 1988;8:207-11.
9. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47.
10. Scanu AM. Lp(a) lipoprotein-coping with heterogeneity. N Engl J Med 2003;349:2089-90.
11. Scanu AM. Lipoprotein(a) and the atherothrombotic process: mechanistic insights and clinical implications. Curr Atheroscler Rep 2003;5:106-13.
12. Walsh JM, Flegel R, Cangianelli LA, et al. Epidemiology of alcohol and other drug use among motor vehicle crash victims admitted to a trauma center. Traffic Inj Prev 2004;5:254-60.
13. Know KT, Rose G. Cholesterol screening programmes: how much potential benefit? BMJ 1989;299:606-7.
14. Basile JN. The importance of systolic blood pressure control and cardiovascular disease prevention. Curr Treat Options Cardiovasc Med 2003;5:271-7.
15. Kannel WB. Elevated systolic blood pressure as a cardiovascular risk factor. Am J Cardiol 2000;85:251-5.
16. Franklin SS, Larson MG, Khan SA, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham heart study. Circulation 2001;103:1245-9.
17. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13.
18. Allison DB, Fontaine KR, Manson JE, et al. Annual deaths attributable to obesity in the United States. JAMA 1999;282:1530-8.
19. Must A, Spadano J, Coakley EH, et al. The disease burden associated with overweight and obesity. JAMA 1999;282:1523-9.
20. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 2004;89:2595-600.
21. Shaper AG. Alcohol and coronary heart disease. Eur Heart J 1995;16:1760-4.
22. Boffetta P, Garfinkel L. Alcohol drinking and mortality among men enrolled in an American Cancer Society prospective study. Epidemiology 1990;1:342-8.
23. Ellison RC. Cheers! Epidemiology 1990;1:337-9.
24. Manson JE, Greenland P, LaCroix AZ, et al. Walking compared with vigorous exercise for the prevention of cardiovascular events in women. N Engl J Med 2002;347:716-25.
25. Manson JE, Hu FB, Rich-Edwards JW, et al. A prospective study of walking as compared with vigorous exercise in the prevention of coronary heart disease in women. N Engl J Med 1999;341:650-8.
26. Lee IM, Rexrode KM, Cook NR, et al. Physical activity and coronary heart disease in women: is "no pain, no gain" passe? JAMA 2001;285:1447-54.
27. Sesso HD, Paffenbarger RS, Ha T, et al. Physical activity and cardiovascular disease risk in middle-aged and older women. Am J Epidemiol 1999;150:408-16.
28. Gregg EW, Cauley JA, Stone K, et al. Relationship of changes in physical activity and mortality among older women. JAMA 2003;289:2379-86.
29. Fleming DM, Schellevis FG, Van CV. The prevalence of known diabetes in eight European countries. Eur J Public Health 2004;14:10-14.
30. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
31. NCEP. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486-97.
32. Sowers JR, Epstein M, Frohlich, eds. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001;37:1053-9.
33. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93.
34. Stampfer MJ, Colditz GA, Willett WC. Menopause and heart disease. A review. Ann N Y Acad Sci 1990;592:193-203; discussion 257-62,193-203.
35. Barrett-Connor E, Goodman-Gruen D. Prospective study of endogenous sex hormones and fatal cardiovascular disease in postmenopausal women. BMJ 1995;311:1193-6.
36. Wu FC, von Eckardstein A. Androgens and coronary artery disease. Endocr Rev 2003;24:183-217.
37. Mosca L, Appel U, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation 2004;109:672-93.
38. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-12.
39. Stevenson JC, Flather M, Collins P. Coronary heart disease in women. N Engl J Med 2000;343:1891-3.
40. Clarke S, Kelleher H, Lloyd-Jones L, et al. Transdermal hormone replacement therapy for secondary prevention of coronary artery disease in postmenopausal women [abstract]. Eur Heart J 2000;21:212.
41. Cherry N, Gilmour K, Hannaford P, et al. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet 2002;360:2001-8.
42. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 2002;288:321-33.
43. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women's health initiative randomized controlled trial. JAMA 2004;291:1701-12.
44. Mosca L, Collins P, Herrington DM, et al. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 2001;104:499-503.
45. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30.
46. Collins P. Clinical cardiovascular studies of hormone replacement therapy. Am J Cardiol 2002;90:F30-4.
47. Harman SM, Brinton EA, Cedars M, et al. KEEPS: The Kronos early estrogen prevention study. Climacteric 2005;8:3-12.